%0 Journal Article
%T Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.
%A Wang Y
%A Jiang H
%A Li M
%A Xu Z
%A Xu H
%A Chen Y
%A Chen K
%A Zheng W
%A Lin W
%A Liu Z
%A Lin Z
%A Zhang M
%J Gene
%V 927
%N 0
%D 2024 Nov 15
%M 38945310
%F 3.913
%R 10.1016/j.gene.2024.148733
%X The adeno-associated virus (AAV) is a defective single-stranded DNA virus with the simplest structure reported to date. It constitutes a capsid protein and single-stranded DNA. With its high transduction efficiency, low immunogenicity, and tissue specificity, it is the most widely used and promising gene therapy vector. The clustered regularly interspaced short palindromic sequence (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing system is an emerging technology that utilizes cas9 nuclease to specifically recognize and cleave target genes under the guidance of small guide RNA and realizes gene editing through homologous directional repair and non-homologous recombination repair. In recent years, an increasing number of animal experiments and clinical studies have revealed the great potential of AAV as a vector to deliver the CRISPR/cas9 system for treating genetic diseases and viral infections. However, the immunogenicity, toxicity, low transmission efficiency in brain and ear tissues, packaging size limitations of AAV, and immunogenicity and off-target effects of Cas9 protein pose several clinical challenges. This research reviews the role, challenges, and countermeasures of the AAV-CRISPR/cas9 system in gene therapy.